CG Oncology Inc. (CGON)
CGON trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/0001193125-26-079498-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CGON on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001991792 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.0M |
| Net income | -$161.0M |
| Operating income | -$190.8M |
| Net margin | -3985.0% |
| Operating margin | -4722.1% |
| Revenue growth | +254.7% |
| Cash | $32.5M |
| Total assets | $791.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1874.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $28.2M cash; operating cash flow -$46.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 89,318,916 (2026-11-04); 80,666,179 a year earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Irvine, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $24.8M, sold $5.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.6M | -$56.9M | -$47.7M | $28.2M | $3.0M | $6.2M | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $1.2M | -$79.1M | -$46.4M | $19.6M | $3.0M | $6.2M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $1.1M | -$60.2M | -$56.9M | $33.7M | $3.0M | $5.1M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $2.3M | -$41.3M | -$36.2M | $32.5M | $3.0M | $4.0M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $1.7M | -$43.8M | -$38.9M | $45.1M | $3.0M | $2.2M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $0 | -$41.4M | -$28.0M | $14.6M | No debt tags | $551K | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $52K | -$34.5M | -$29.3M | $41.5M | No debt tags | $662K | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $456K | -$31.8M | -$20.7M | $257.1M | $0 | $1.1M | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-06 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 246 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.1% |
| 1 month | +19.2% |
| 3 months | -0.4% |
| Year to date | +79.2% |
| 1 year | +97.0% |
| From 52-week high | -7.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TWST | Twist Bioscience Corporation | $105.04 | -5.88% | $7.0B |
| IMVT | Immunovant Inc. | $33.28 | -2.63% | $6.9B |
| KOD | Kodiak Sciences Inc | $100.73 | -9.41% | $6.6B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| IBRX | ImmunityBio Inc. | $5.98 | -0.66% | $6.4B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier